0|chunk|The Amino-Terminal Region of Hepatitis E Virus ORF1 Containing a Methyltransferase (Met) and a Papain-Like Cysteine Protease (PCP) Domain Counteracts Type I Interferon Response
0	84	87 Met	Chemical	CHEBI_16044
0	84	87 Met	Chemical	CHEBI_16811
0	107	115 Cysteine	Chemical	CHEBI_15356
0	126	129 PCP	Chemical	CHEBI_17642
0	157	167 Interferon	Chemical	CHEBI_52999
0	CHEBI-CHEBI	CHEBI_16044	CHEBI_16811
0	CHEBI-CHEBI	CHEBI_16044	CHEBI_15356
0	CHEBI-CHEBI	CHEBI_16044	CHEBI_17642
0	CHEBI-CHEBI	CHEBI_16044	CHEBI_52999
0	CHEBI-CHEBI	CHEBI_16811	CHEBI_15356
0	CHEBI-CHEBI	CHEBI_16811	CHEBI_17642
0	CHEBI-CHEBI	CHEBI_16811	CHEBI_52999
0	CHEBI-CHEBI	CHEBI_15356	CHEBI_17642
0	CHEBI-CHEBI	CHEBI_15356	CHEBI_52999
0	CHEBI-CHEBI	CHEBI_17642	CHEBI_52999

1|chunk|Hepatitis E virus (HEV) is responsible for large waterborne epidemics of hepatitis in endemic countries and is an emerging zoonotic pathogen worldwide. In endemic regions, HEV-1 or HEV-2 genotypes are frequently associated with fulminant hepatitis in pregnant women, while with zoonotic HEV (HEV-3 and HEV-4), chronic cases of hepatitis and severe neurological disorders are reported. Hence, it is important to characterize the interactions between HEV and its host. Here, we investigated the ability of the nonstructural polyprotein encoded by the first open reading frame (ORF1) of HEV to modulate the host early antiviral response and, in particular, the type I interferon (IFN-I) system. We found that the amino-terminal region of HEV-3 ORF1 (MetYPCP), containing a putative methyltransferase (Met) and a papain-like cysteine protease (PCP) functional domain, inhibited IFN-stimulated response element (ISRE) promoter activation and the expression of several IFN-stimulated genes (ISGs) in response to IFN-I. We showed that the MetYPCP domain interfered with the Janus kinase (JAK)/signal transducer and activator of the transcription protein (STAT) signalling pathway by inhibiting STAT1 nuclear translocation and phosphorylation after IFN-I treatment. In contrast, MetYPCP had no effect on STAT2 phosphorylation and a limited impact on the activation of the JAK/STAT pathway after IFN-II stimulation. This inhibitory function seemed to be genotype-dependent, as MetYPCP from HEV-1 had no significant effect on the JAK/STAT pathway. Overall, this study provides evidence that the predicted MetYPCP domain of HEV ORF1 antagonises STAT1 activation to modulate the IFN response.
1	615	624 antiviral	Chemical	CHEBI_22587
1	665	675 interferon	Chemical	CHEBI_52999
1	798	801 Met	Chemical	CHEBI_16044
1	798	801 Met	Chemical	CHEBI_16811
1	821	829 cysteine	Chemical	CHEBI_15356
1	840	843 PCP	Chemical	CHEBI_17642
1	898	905 element	Chemical	CHEBI_33250
1	1139	1146 protein	Chemical	CHEBI_16541
1	1165	1172 pathway	Chemical	CHEBI_34922
1	1373	1380 pathway	Chemical	CHEBI_34922
1	1529	1536 pathway	Chemical	CHEBI_34922
1	CHEBI-CHEBI	CHEBI_22587	CHEBI_52999
1	CHEBI-CHEBI	CHEBI_22587	CHEBI_16044
1	CHEBI-CHEBI	CHEBI_22587	CHEBI_16811
1	CHEBI-CHEBI	CHEBI_22587	CHEBI_15356
1	CHEBI-CHEBI	CHEBI_22587	CHEBI_17642
1	CHEBI-CHEBI	CHEBI_22587	CHEBI_33250
1	CHEBI-CHEBI	CHEBI_22587	CHEBI_16541
1	CHEBI-CHEBI	CHEBI_22587	CHEBI_34922
1	CHEBI-CHEBI	CHEBI_52999	CHEBI_16044
1	CHEBI-CHEBI	CHEBI_52999	CHEBI_16811
1	CHEBI-CHEBI	CHEBI_52999	CHEBI_15356
1	CHEBI-CHEBI	CHEBI_52999	CHEBI_17642
1	CHEBI-CHEBI	CHEBI_52999	CHEBI_33250
1	CHEBI-CHEBI	CHEBI_52999	CHEBI_16541
1	CHEBI-CHEBI	CHEBI_52999	CHEBI_34922
1	CHEBI-CHEBI	CHEBI_16044	CHEBI_16811
1	CHEBI-CHEBI	CHEBI_16044	CHEBI_15356
1	CHEBI-CHEBI	CHEBI_16044	CHEBI_17642
1	CHEBI-CHEBI	CHEBI_16044	CHEBI_33250
1	CHEBI-CHEBI	CHEBI_16044	CHEBI_16541
1	CHEBI-CHEBI	CHEBI_16044	CHEBI_34922
1	CHEBI-CHEBI	CHEBI_16811	CHEBI_15356
1	CHEBI-CHEBI	CHEBI_16811	CHEBI_17642
1	CHEBI-CHEBI	CHEBI_16811	CHEBI_33250
1	CHEBI-CHEBI	CHEBI_16811	CHEBI_16541
1	CHEBI-CHEBI	CHEBI_16811	CHEBI_34922
1	CHEBI-CHEBI	CHEBI_15356	CHEBI_17642
1	CHEBI-CHEBI	CHEBI_15356	CHEBI_33250
1	CHEBI-CHEBI	CHEBI_15356	CHEBI_16541
1	CHEBI-CHEBI	CHEBI_15356	CHEBI_34922
1	CHEBI-CHEBI	CHEBI_17642	CHEBI_33250
1	CHEBI-CHEBI	CHEBI_17642	CHEBI_16541
1	CHEBI-CHEBI	CHEBI_17642	CHEBI_34922
1	CHEBI-CHEBI	CHEBI_33250	CHEBI_16541
1	CHEBI-CHEBI	CHEBI_33250	CHEBI_34922
1	CHEBI-CHEBI	CHEBI_16541	CHEBI_34922

2|chunk|Viruses 2018, 10, 726 2 of 21 reading frames (ORF1 to 3) [2]. ORF1 codes for a nonstructural polyprotein composed of several putative functional domains including a methyltransferase (Met), a domain of unknown function (Y), a papain-like cysteine protease (PCP), a macrodomain (X), a helicase and an RNA-dependent RNA polymerase (RdRp) [3] . It is still unclear whether ORF1 is expressed as a single polyprotein or cleaved to several functional proteins in the context of infection. Multiple studies have suggested that ORF1 is cleaved into several products [4] [5] [6] [7] [8] , whereas a few others have reported a lack of processing of the viral polyprotein [9] [10] [11] . The use of different expression systems may explain these conflicting results. Recently, a paper has suggested that ORF1 is cleaved by thrombin and factor Xa [12] . ORF2 and ORF3 code for the capsid protein and a multifunctional phosphoprotein, respectively. Four genotypes infect humans. Genotypes 1 and 2 (HEV-1 and HEV-2) are transmitted via the faecal-oral route, through the consumption of contaminated water or soiled food in endemic regions. In contrast, genotypes 3 and 4 (HEV-3 and HEV-4) are detected in humans and other animal species worldwide and are transmitted via direct contact with infected animals or the consumption of infected meat [13, 14] . In most human cases, HEV infection causes an acute hepatitis that is self-limited. However, fulminant hepatic failure can occur in pregnant women in endemic regions (HEV-1 or -2), in patients with underlying chronic liver disease, or in the elderly (HEV-3 or -4). More recently, chronic cases of hepatitis E have been reported in immunocompromised patients (HEV-3 or HEV-4) and extrahepatic manifestations including renal, pancreatic and neurological disorders have been linked to HEV infection [15] . With the exception of China, no country has yet commercialized an HEV vaccine, and no treatment against HEV infection is approved.
2	238	246 cysteine	Chemical	CHEBI_15356
2	314	317 RNA	Chemical	CHEBI_33697
2	445	453 proteins	Chemical	CHEBI_36080
2	812	820 thrombin	Chemical	CHEBI_9574
2	876	883 protein	Chemical	CHEBI_16541
2	1085	1090 water	Chemical	CHEBI_15377
2	1101	1105 food	Chemical	CHEBI_33290
2	CHEBI-CHEBI	CHEBI_15356	CHEBI_33697
2	CHEBI-CHEBI	CHEBI_15356	CHEBI_36080
2	CHEBI-CHEBI	CHEBI_15356	CHEBI_9574
2	CHEBI-CHEBI	CHEBI_15356	CHEBI_16541
2	CHEBI-CHEBI	CHEBI_15356	CHEBI_15377
2	CHEBI-CHEBI	CHEBI_15356	CHEBI_33290
2	CHEBI-CHEBI	CHEBI_33697	CHEBI_36080
2	CHEBI-CHEBI	CHEBI_33697	CHEBI_9574
2	CHEBI-CHEBI	CHEBI_33697	CHEBI_16541
2	CHEBI-CHEBI	CHEBI_33697	CHEBI_15377
2	CHEBI-CHEBI	CHEBI_33697	CHEBI_33290
2	CHEBI-CHEBI	CHEBI_36080	CHEBI_9574
2	CHEBI-CHEBI	CHEBI_36080	CHEBI_16541
2	CHEBI-CHEBI	CHEBI_36080	CHEBI_15377
2	CHEBI-CHEBI	CHEBI_36080	CHEBI_33290
2	CHEBI-CHEBI	CHEBI_9574	CHEBI_16541
2	CHEBI-CHEBI	CHEBI_9574	CHEBI_15377
2	CHEBI-CHEBI	CHEBI_9574	CHEBI_33290
2	CHEBI-CHEBI	CHEBI_16541	CHEBI_15377
2	CHEBI-CHEBI	CHEBI_16541	CHEBI_33290
2	CHEBI-CHEBI	CHEBI_15377	CHEBI_33290

3|chunk|Interferons (IFNs) are a group of secreted cytokines that play a key role in the host early antiviral response. Type I IFNs (IFN-I), composed mainly of IFN- and , are produced directly in response to viral infection, upon the sensing of viral molecular signatures by specialized cellular receptors such as retinoic-acid-inducible gene (RIG)-I-like receptors (RLRs) and Toll-like receptors (TLRs). IFN-I subsequently binds to IFN-/ receptors (IFNAR) at the cell surface and activates the Janus kinase (JAK)/signal transducer and activator of transcription protein (STAT) signalling pathway in an autocrine and paracrine manner. The binding of IFN-I to receptors leads to the phosphorylation of tyrosine kinase 2 (TYK2) and JAK1 [16] [17] [18] and the subsequent phosphorylation of the cytoplasmic domain of the IFNAR subunits [18] [19] [20] [21] [22] . STAT1 and STAT2 are then recruited and phosphorylated by the JAK kinases on tyrosine 701 and tyrosine 690, respectively [18, 23] . Phosphorylated STAT1/STAT2 heterodimers are released in the cytoplasm, where they interact with IFN response factor 9 (IRF9) to form IFN-stimulated gene (ISG) factor 3 (ISGF3). This transcription factor translocates to the nucleus, where it binds to specific promoter elements called IFN-stimulated response elements (ISRE), leading to the upregulation of hundreds of IFN-stimulated genes (ISGs) that may display antiviral properties and contribute to the establishment of a rapid and robust antiviral state within the cell [24] . Most cells can produce IFN-I. In contrast, type II IFN (IFN-) is secreted mainly by activated T cells and natural killer cells. The binding of the cytokine to a specific IFN- receptor (IFNGR) leads to the phosphorylation of JAK1 and JAK2 and the subsequent phosphorylation of STAT1. STAT1 homodimers are then formed and translocate to the nucleus where they bind to specific promoters to activate the transcription of a different subset of ISGs [25] .
3	69	73 role	Chemical	CHEBI_50906
3	92	101 antiviral	Chemical	CHEBI_22587
3	559	566 protein	Chemical	CHEBI_16541
3	585	592 pathway	Chemical	CHEBI_34922
3	697	705 tyrosine	Chemical	CHEBI_17895
3	697	705 tyrosine	Chemical	CHEBI_18186
3	932	940 tyrosine	Chemical	CHEBI_17895
3	932	940 tyrosine	Chemical	CHEBI_18186
3	949	957 tyrosine	Chemical	CHEBI_17895
3	949	957 tyrosine	Chemical	CHEBI_18186
3	1210	1217 nucleus	Chemical	CHEBI_33252
3	1255	1263 elements	Chemical	CHEBI_33250
3	1295	1303 elements	Chemical	CHEBI_33250
3	1400	1409 antiviral	Chemical	CHEBI_22587
3	1479	1488 antiviral	Chemical	CHEBI_22587
3	1859	1866 nucleus	Chemical	CHEBI_33252
3	CHEBI-CHEBI	CHEBI_50906	CHEBI_22587
3	CHEBI-CHEBI	CHEBI_50906	CHEBI_16541
3	CHEBI-CHEBI	CHEBI_50906	CHEBI_34922
3	CHEBI-CHEBI	CHEBI_50906	CHEBI_17895
3	CHEBI-CHEBI	CHEBI_50906	CHEBI_18186
3	CHEBI-CHEBI	CHEBI_50906	CHEBI_33252
3	CHEBI-CHEBI	CHEBI_50906	CHEBI_33250
3	CHEBI-CHEBI	CHEBI_22587	CHEBI_16541
3	CHEBI-CHEBI	CHEBI_22587	CHEBI_34922
3	CHEBI-CHEBI	CHEBI_22587	CHEBI_17895
3	CHEBI-CHEBI	CHEBI_22587	CHEBI_18186
3	CHEBI-CHEBI	CHEBI_22587	CHEBI_33252
3	CHEBI-CHEBI	CHEBI_22587	CHEBI_33250
3	CHEBI-CHEBI	CHEBI_16541	CHEBI_34922
3	CHEBI-CHEBI	CHEBI_16541	CHEBI_17895
3	CHEBI-CHEBI	CHEBI_16541	CHEBI_18186
3	CHEBI-CHEBI	CHEBI_16541	CHEBI_33252
3	CHEBI-CHEBI	CHEBI_16541	CHEBI_33250
3	CHEBI-CHEBI	CHEBI_34922	CHEBI_17895
3	CHEBI-CHEBI	CHEBI_34922	CHEBI_18186
3	CHEBI-CHEBI	CHEBI_34922	CHEBI_33252
3	CHEBI-CHEBI	CHEBI_34922	CHEBI_33250
3	CHEBI-CHEBI	CHEBI_17895	CHEBI_18186
3	CHEBI-CHEBI	CHEBI_17895	CHEBI_33252
3	CHEBI-CHEBI	CHEBI_17895	CHEBI_33250
3	CHEBI-CHEBI	CHEBI_18186	CHEBI_33252
3	CHEBI-CHEBI	CHEBI_18186	CHEBI_33250
3	CHEBI-CHEBI	CHEBI_33252	CHEBI_33250

4|chunk|Different reports have suggested that an IFN response is triggered by HEV as the expression of IFN-I, and multiple ISGs have been detected after infection in vivo and in vitro [26] [27] [28] [29] [30] [31] . However, IFN-I seem to have a moderate and delayed antiviral effect on HEV infection in vitro and in patients in comparison, for instance, to the potent effect they exert on the hepatitis C virus (HCV), another hepatotropic RNA virus [32, 33] . Consistently, recent studies have indicated that the host ISG response to IFN-I is inhibited during HEV infection [31] [32] [33] [34] , but the mechanisms involved in this inhibition remain poorly characterized. As a nonstructural polyprotein, HEV ORF1 contains one or several functional domains able to modulate the IFN-I system. The macrodomain, the PCP domain and the Met domain have been described as antagonists of the signalling cascade leading to IFN synthesis [35, 36] . However, nothing is known about the ability of the viral polyprotein to inhibit the response to IFN-I
4	259	268 antiviral	Chemical	CHEBI_22587
4	432	435 RNA	Chemical	CHEBI_33697
4	805	808 PCP	Chemical	CHEBI_17642
4	824	827 Met	Chemical	CHEBI_16044
4	824	827 Met	Chemical	CHEBI_16811
4	858	869 antagonists	Chemical	CHEBI_48706
4	CHEBI-CHEBI	CHEBI_22587	CHEBI_33697
4	CHEBI-CHEBI	CHEBI_22587	CHEBI_17642
4	CHEBI-CHEBI	CHEBI_22587	CHEBI_16044
4	CHEBI-CHEBI	CHEBI_22587	CHEBI_16811
4	CHEBI-CHEBI	CHEBI_22587	CHEBI_48706
4	CHEBI-CHEBI	CHEBI_33697	CHEBI_17642
4	CHEBI-CHEBI	CHEBI_33697	CHEBI_16044
4	CHEBI-CHEBI	CHEBI_33697	CHEBI_16811
4	CHEBI-CHEBI	CHEBI_33697	CHEBI_48706
4	CHEBI-CHEBI	CHEBI_17642	CHEBI_16044
4	CHEBI-CHEBI	CHEBI_17642	CHEBI_16811
4	CHEBI-CHEBI	CHEBI_17642	CHEBI_48706
4	CHEBI-CHEBI	CHEBI_16044	CHEBI_16811
4	CHEBI-CHEBI	CHEBI_16044	CHEBI_48706
4	CHEBI-CHEBI	CHEBI_16811	CHEBI_48706

